TLDR Upadacitinib may effectively treat resistant lichen planopilaris.
This case series explores the treatment of recalcitrant lichen planopilaris (LPP) with upadacitinib, a Janus kinase (JAK) inhibitor. The study, conducted by the Department of Dermatology at La Fe University and Polytechnic Hospital in Valencia, Spain, presents evidence that upadacitinib may be an effective treatment option for patients with LPP who have not responded to other therapies. The authors report positive outcomes in the cases treated, suggesting that JAK inhibitors could play a significant role in managing this challenging condition. No conflicts of interest or funding sources were reported.
220 citations,
June 2013 in “The Journal of Pathology” Lichen planopilaris may be an autoimmune disease causing hair loss due to immune system issues in hair follicles.
3 citations,
December 2022 in “Cells” Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.
November 2024 in “Medicina” Recognizing scalp symptoms in PRP is crucial for proper diagnosis and treatment.
3 citations,
July 2023 in “International journal of molecular sciences” Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
329 citations,
January 1997 in “Journal of the American Academy of Dermatology” Frontal fibrosing alopecia is a hair loss condition in postmenopausal women, similar to lichen planopilaris, with ineffective treatments.
220 citations,
June 2013 in “The Journal of Pathology” Lichen planopilaris may be an autoimmune disease causing hair loss due to immune system issues in hair follicles.